Header Logo

Connection

Jinal Bhiman to Antibodies, Neutralizing

This is a "connection" page, showing publications Jinal Bhiman has written about Antibodies, Neutralizing.
Connection Strength

4,091
  1. Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
    View in: PubMed
    Score: 0,798
  2. Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep. 2017 04; 14(2):54-62.
    View in: PubMed
    Score: 0,463
  3. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,418
  4. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
    View in: PubMed
    Score: 0,191
  5. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023 01 21; 13(1):1222.
    View in: PubMed
    Score: 0,173
  6. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,164
  7. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022 02; 602(7898):654-656.
    View in: PubMed
    Score: 0,160
  8. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun. 2021 08 10; 12(1):4817.
    View in: PubMed
    Score: 0,156
  9. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
    View in: PubMed
    Score: 0,153
  10. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,152
  11. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
    View in: PubMed
    Score: 0,143
  12. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
    View in: PubMed
    Score: 0,128
  13. Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 2018 08; 53:143-151.
    View in: PubMed
    Score: 0,125
  14. Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. Immunity. 2017 05 16; 46(5):762-764.
    View in: PubMed
    Score: 0,117
  15. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,114
  16. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
    View in: PubMed
    Score: 0,106
  17. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,104
  18. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,093
  19. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,091
  20. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,085
  21. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories. Viruses. 2024 12 18; 16(12).
    View in: PubMed
    Score: 0,049
  22. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 03; 603(7902):679-686.
    View in: PubMed
    Score: 0,040
  23. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
    View in: PubMed
    Score: 0,034
  24. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.